文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

一线抗逆转录病毒治疗失败时M184V/I突变与病毒载量及L74I补偿突变的关系

Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
PubMed 文献 · J Infect Dis · 2020-01-01

L74I仅见于10.2%的M184V/I者,体外可补偿M184V的复制缺陷。结论未发现含TDF/XTC/NNRTI方案失败时XTC仍有获益的证据。

要点

  • 病毒学失败者中M184V/I携带率为56.5%,伴或不伴该突变者病毒载量相似。
  • L74I仅出现在M184V/I阳性者中(10.2%),体外可补偿M184V复制缺陷。
  • 含TDF/XTC/NNRTI一线方案失败时,未发现XTC保留获益的证据。

核心结论

  • 在含TDF/XTC/NNRTI方案病毒学失败者中,伴或不伴M184V/I突变者病毒载量相似,未发现XTC保留获益的证据。

研究设计与样本

  • 采用随机效应荟萃分析比较病毒学失败者中伴或不伴M184V/I的病毒载量,并进行体外逆转录酶活性与感染性分析。
  • 纳入1445例病毒学失败个体,其中817例(56.5%)携带M184I/V。

主要发现

  • 发生M184V/I者在抗逆转录病毒治疗启动时和病毒学失败时的CD4计数均较低。
  • L74I存在于10.2%的M184V/I者中,而不伴M184V/I者中缺失(P < .0001)。
  • 体外实验显示L74I可补偿M184V突变病毒的复制缺陷。

临床怎么用

  • 含TDF/XTC/NNRTI一线方案失败且检出M184V/I时,不应基于XTC保留活性而继续该方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: M184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility. Nonetheless, 3TC and FTC (collectively referred to as XTC) appear to retain modest activity against human immunodeficiency virus-1 with these mutations possibly as a result of reduced replication capacity. In this study, we determined how M184V/I impacts virus load (VL) in patients failing therapy on a TDF/XTC plus nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regimen. METHODS: We compared VL in the absence and presence of M184V/I across studies using random effects meta-analysis. The effect of mutations on virus reverse-transcriptase activity and infectiousness was analyzed in vitro. RESULTS: M184I/V was present in 817 (56.5%) of 1445 individuals with virologic failure (VF). Virus load was similar in individuals with or without M184I/V (difference in log10 VL, 0.18; 95% confidence interval, .05-.31). CD4 count was lower both at initiation of antiretroviral therapy and at VF in participants who went on to develop M184V/I. L74I was present in 10.2% of persons with M184V/I but absent in persons without M184V/I (P < .0001). In vitro, L74I compensated for defective replication of M184V-mutated virus. CONCLUSIONS: Virus loads were similar in persons with and without M184V/I during VF on a TDF/XTC/NNRTI-containing regimen. Therefore, we did not find evidence for a benefit of XTC in the context of first-line failure on this combination.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gregson J, Rhee SY, Datir R, et al. Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I. J Infect Dis. 2020. PMID: 31774913. doi:10.1093/infdis/jiz631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。